Insider · CIK 0001388325
Novo Holdings A/S
Files at AVLN (Avalyn Pharma Inc.), MPLT (MapLight Therapeutics, Inc.), COAG (Hemab Therapeutics Holdings, Inc.). First filing Oct 30, 2025, latest May 5, 2026.
Novo Holdings A/S files SEC Form 4 as 10% owner at AVLN (Avalyn Pharma Inc.), and also at MPLT (MapLight Therapeutics, Inc.), COAG (Hemab Therapeutics Holdings, Inc.). Since Oct 30, 2025, Novo Holdings A/S has reported 2 open-market buys worth $26M and 0 open-market sells worth $0, the latest filed on May 5, 2026.
A track record needs three past buys with six months of prices behind them; Novo Holdings A/S has 0, so none is measured yet.
The newest scored trade: bought $10.0M of AVLN on May 1, 2026, filed May 5, 2026, scored 50 (moderate). In the last 12 months: 2 buys worth $26M and 0 sells worth $0.
Where the trades landed
Last year at the 2 companies this insider has traded most, with each buy and sell on the bar it happened.
AVLN: Avalyn Pharma Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
MPLT: MapLight Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | Avalyn Pharma Inc. | $10.0M 555,555 shares | +17% | - | |
| 56Moderate | MapLight Therapeutics, Inc. | $16M 952,941 shares | +35% | 0% from low-9% from high |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 4, 2026 | COAG Hemab Therapeutics Holdings, Inc. | CConversion Common Stock | +4,180,550 | - | - | 4,180,550 | May 6, 2026 |
| May 4, 2026 | COAG Hemab Therapeutics Holdings, Inc. | CConversion Series Seed Preferred Stockderivative | -23,343 | $0.00 | $0 | 0 | May 6, 2026 |
| May 4, 2026 | COAG Hemab Therapeutics Holdings, Inc. | CConversion Series A Preferred Stockderivative | -71,866 | $0.00 | $0 | 0 | May 6, 2026 |
| May 4, 2026 | COAG Hemab Therapeutics Holdings, Inc. | CConversion Series B Preferred Stockderivative | -62,121 | $0.00 | $0 | 0 | May 6, 2026 |
| May 4, 2026 | COAG Hemab Therapeutics Holdings, Inc. | CConversion Series C Preferred Stockderivative | -32,695 | $0.00 | $0 | 0 | May 6, 2026 |
| May 1, 2026 | AVLN Avalyn Pharma Inc. | CConversion Voting Common Stock | +3,327,734 | - | - | 3,327,734 | May 5, 2026 |
| May 1, 2026 | AVLN Avalyn Pharma Inc. | POpen-market purchase Voting Common Stock | +555,555 | $18.00 | $10.0M | 3,883,289 | May 5, 2026 |
| May 1, 2026 | AVLN Avalyn Pharma Inc. | CConversion Series A Preferred Stockderivative | -18,000,000 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | AVLN Avalyn Pharma Inc. | CConversion Series B Preferred Stockderivative | -1,986,369 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | AVLN Avalyn Pharma Inc. | CConversion Series C-1 Preferred Stockderivative | -25,899,284 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | AVLN Avalyn Pharma Inc. | CConversion Series C-2 Preferred Stockderivative | -5,587,603 | $0.00 | $0 | 0 | May 5, 2026 |
| May 1, 2026 | AVLN Avalyn Pharma Inc. | CConversion Series D Preferred Stockderivative | -12,558,081 | $0.00 | $0 | 0 | May 5, 2026 |
| Oct 28, 2025 | MPLT MapLight Therapeutics, Inc. | CConversion Voting Common Stock | +2,733,681 | - | - | 2,733,681 | Oct 30, 2025 |
| Oct 28, 2025 | MPLT MapLight Therapeutics, Inc. | POpen-market purchase Voting Common Stock | +952,941 | $17.00 | $16M | 3,686,622 | Oct 30, 2025 |
| Oct 28, 2025 | MPLT MapLight Therapeutics, Inc. | CConversion Series C Preferred Stockderivative | -26,191,207 | $0.00 | $0 | 0 | Oct 30, 2025 |
| Oct 28, 2025 | MPLT MapLight Therapeutics, Inc. | CConversion Series D Preferred Stockderivative | -19,734,671 | $0.00 | $0 | 0 | Oct 30, 2025 |
Questions about Novo Holdings A/S
Answered from the filings on this page, as of the latest one.
Is Novo Holdings A/S buying or selling?
In the last 12 months Novo Holdings A/S reported 2 open-market buys worth $26M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $10.0M of AVLN on May 1, 2026. Grants, option exercises and tax withholding are not counted.
How did Novo Holdings A/S's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Novo Holdings A/S has 0.
Where does Novo Holdings A/S file Form 4?
Novo Holdings A/S has filed Form 4 at AVLN (Avalyn Pharma Inc.); MPLT (MapLight Therapeutics, Inc.); COAG (Hemab Therapeutics Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.